JP2019529481A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019529481A5 JP2019529481A5 JP2019516972A JP2019516972A JP2019529481A5 JP 2019529481 A5 JP2019529481 A5 JP 2019529481A5 JP 2019516972 A JP2019516972 A JP 2019516972A JP 2019516972 A JP2019516972 A JP 2019516972A JP 2019529481 A5 JP2019529481 A5 JP 2019529481A5
- Authority
- JP
- Japan
- Prior art keywords
- theta
- crystalline form
- compound
- crystal
- starting temperature
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000013078 crystal Substances 0.000 claims description 25
- 150000001875 compounds Chemical class 0.000 claims description 18
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 18
- 238000000113 differential scanning calorimetry Methods 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 9
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 6
- 238000001816 cooling Methods 0.000 claims description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 239000002904 solvent Substances 0.000 claims description 4
- 239000003085 diluting agent Substances 0.000 claims description 2
- 201000010099 disease Diseases 0.000 claims description 2
- 208000035475 disorder Diseases 0.000 claims description 2
- 238000001035 drying Methods 0.000 claims description 2
- 238000001914 filtration Methods 0.000 claims description 2
- 230000001404 mediated effect Effects 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 238000003828 vacuum filtration Methods 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 2
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662402813P | 2016-09-30 | 2016-09-30 | |
| US62/402,813 | 2016-09-30 | ||
| PCT/US2017/054227 WO2018064441A1 (en) | 2016-09-30 | 2017-09-29 | Crystalline forms of a bile acid derivative |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019529481A JP2019529481A (ja) | 2019-10-17 |
| JP2019529481A5 true JP2019529481A5 (enExample) | 2020-09-17 |
Family
ID=61760943
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019516972A Withdrawn JP2019529481A (ja) | 2016-09-30 | 2017-09-29 | 胆汁酸誘導体の結晶形態 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20200024299A1 (enExample) |
| EP (1) | EP3518937A4 (enExample) |
| JP (1) | JP2019529481A (enExample) |
| KR (1) | KR20190057108A (enExample) |
| CN (1) | CN109963567A (enExample) |
| AU (1) | AU2017336803A1 (enExample) |
| BR (1) | BR112019006242A2 (enExample) |
| CA (1) | CA3038534A1 (enExample) |
| IL (1) | IL265621A (enExample) |
| MX (1) | MX2019003684A (enExample) |
| WO (1) | WO2018064441A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021071837A1 (en) | 2019-10-07 | 2021-04-15 | Kallyope, Inc. | Gpr119 agonists |
| BR112022017039A2 (pt) | 2020-02-28 | 2022-11-16 | Kallyope Inc | Agonistas de gpr40 |
| JP2023526625A (ja) | 2020-05-19 | 2023-06-22 | キャリーオペ，インク． | Ａｍｐｋアクチベーター |
| CN116390925A (zh) | 2020-06-26 | 2023-07-04 | 卡尔优普公司 | Ampk活化剂 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2040713B1 (en) * | 2006-06-27 | 2014-06-18 | Intercept Pharmaceuticals Inc. | Bile acid derivatives as fxr ligands for the prevention or treatment of fxr-mediated deseases or conditions |
| CA2666603C (en) * | 2006-10-16 | 2013-08-06 | Pfizer Products Inc. | Therapeutic pyrazolyl thienopyridines and uses thereof for treating tgf.beta. mediated conditions |
| WO2009051112A1 (ja) * | 2007-10-15 | 2009-04-23 | Takeda Pharmaceutical Company Limited | アミド化合物およびその用途 |
| EP2468762A1 (en) * | 2010-11-30 | 2012-06-27 | Dr. Falk Pharma Gmbh | Optimized synthesis of pure, non-polymorphic, crystalline bile acids with defined particle size |
| CA2877122C (en) * | 2012-06-19 | 2020-04-28 | Intercept Pharmaceuticals, Inc. | Preparation, uses and solid forms of obeticholic acid |
| KR102068381B1 (ko) * | 2012-10-26 | 2020-01-20 | 인터셉트 파마슈티컬즈, 인크. | 담즙산 유도체의 제조 방법 |
| CA2891348C (en) * | 2012-11-28 | 2020-04-28 | Intercept Pharmaceuticals, Inc. | Treatment of pulmonary disease |
| HUP1300504A2 (en) * | 2013-08-27 | 2015-03-30 | Egis Gyogyszergyar Nyilvanosan Muekoedoe Reszvenytarsasag | Sorafenib salts |
| AU2016306297A1 (en) * | 2015-08-07 | 2018-02-22 | Intercept Pharmaceuticals, Inc. | Methods for preparation of bile acids and derivatives thereof |
| US11072631B2 (en) * | 2015-09-24 | 2021-07-27 | Intercept Pharmaceuticals, Inc. | Methods and intermediates for the preparation bile acid derivatives |
-
2017
- 2017-09-29 KR KR1020197012131A patent/KR20190057108A/ko not_active Withdrawn
- 2017-09-29 AU AU2017336803A patent/AU2017336803A1/en not_active Abandoned
- 2017-09-29 MX MX2019003684A patent/MX2019003684A/es unknown
- 2017-09-29 JP JP2019516972A patent/JP2019529481A/ja not_active Withdrawn
- 2017-09-29 EP EP17857474.5A patent/EP3518937A4/en not_active Withdrawn
- 2017-09-29 CN CN201780071347.7A patent/CN109963567A/zh active Pending
- 2017-09-29 BR BR112019006242A patent/BR112019006242A2/pt not_active IP Right Cessation
- 2017-09-29 WO PCT/US2017/054227 patent/WO2018064441A1/en not_active Ceased
- 2017-09-29 CA CA3038534A patent/CA3038534A1/en not_active Abandoned
- 2017-09-29 US US16/337,982 patent/US20200024299A1/en not_active Abandoned
-
2019
- 2019-03-26 IL IL265621A patent/IL265621A/en unknown